{"filing":{"accession_number":"0001477932-26-004556","cik":"0001737523","ticker":"BGLC","company_name":"BioNexus Gene Lab Corp","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"bglc_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/bglc_8k.htm"},"events":[{"id":21010,"run_id":18934,"accession_number":"0001477932-26-004556","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This disclosure announces progress toward commercializing the VitaGuard™ MRD platform in Southeast Asia following a working visit to Tongshu Gene facilities in China. The filing describes technical and commercial planning, hospital site visits, and next steps for laboratory implementation and regulatory preparation. This is a material operational and strategic milestone—the company is advancing a key product toward market entry in a licensed region—but does not fit neatly into specific event categories (not M\u0026A, not a material impairment, not a workforce action). The event is clearly operational/strategic in nature and material to investors assessing the company's progress on its precision diagnostics business.","company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20541,"accession_number":"0001477932-26-004556","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces progress toward commercializing the VitaGuard™ MRD platform in Southeast Asia following a working visit to Tongshu Gene facilities in China. The filing describes technical and commercial planning, hospital site visits, and next steps for laboratory implementation and regulatory preparation. This is a material operational and strategic milestone—the company is advancing a key product toward market entry in a licensed region—but does not fit neatly into specific event categories (not M\u0026A, not a material impairment, not a workforce action). The event is clearly operational/strategic in nature and material to investors assessing the company's progress on its precision diagnostics business.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T18:32:00.903730+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20541,"accession_number":"0001477932-26-004556","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces progress toward commercializing the VitaGuard™ MRD platform in Southeast Asia following a working visit to Tongshu Gene facilities in China. The filing describes technical and commercial planning, hospital site visits, and next steps for laboratory implementation and regulatory preparation. This is a material operational and strategic milestone—the company is advancing a key product toward market entry in a licensed region—but does not fit neatly into specific event categories (not M\u0026A, not a material impairment, not a workforce action). The event is clearly operational/strategic in nature and material to investors assessing the company's progress on its precision diagnostics business.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T18:32:00.903730+00:00","company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","filing_date":"2026-07-28"}]}